Scandinavian Journal of Urology and Nephrology最新文献

{"title":"Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer.","authors":"Jørgen Bjerggaard Jensen,&nbsp;Benedicte Parm Ulhøi,&nbsp;Klaus Møller-Ernst Jensen","doi":"10.3109/00365599.2011.609832","DOIUrl":"https://doi.org/10.3109/00365599.2011.609832","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prognostic value of lymph-node dissection (LND) in patients undergoing radical cystectomy (RC) following previous oncological treatment.</p><p><strong>Material and methods: </strong>Perioperative findings and recurrence patterns of 46 patients undergoing RC for bladder cancer were evaluated. Twenty-six patients underwent salvage cystectomy because of local bladder cancer recurrence following intended curative external beam radiotherapy; 20 patients underwent preoperative chemotherapy because of non-regional lymph-node metastases (10 patients), clinically fixed primary tumour (cT4b) (eight patients) or pulmonary metastases (two patients).</p><p><strong>Results: </strong>Difficulties with LND because of fibrous tissue were accounted in the majority of previously irradiated patients. No metastatic lymph nodes were found within the irradiation field at the time of surgery or during follow-up. Two- and 5-year disease-specific survival (DSS) was 47% and 31%, respectively. In patients undergoing preoperative chemotherapy because of lymph-node metastasis, three patients (30%) had vital tumour cells within the removed lymph-nodes. Two- and 5-year DSS was 67% and 50%, respectively. Despite preoperative chemotherapy, all patients with cT4b tumours and previously diagnosed pulmonary metastases died because of recurrent disease within 2 years.</p><p><strong>Conclusions: </strong>LND in the previously irradiated pelvis may be difficult and remains controversial. Because of a high risk of vital tumours cells within the removed lymph nodes despite chemotherapy, extended LND should be performed in patients with non-regional lymph-node metastasis following preoperative chemotherapy. In patients with fixed tumours and minimal response to chemotherapy and in patients with visceral metastases, RC should be attempted for palliative reasons only.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 6","pages":"436-43"},"PeriodicalIF":0.0,"publicationDate":"2011-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.609832","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30087949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hereditary persistence of alpha-fetoprotein mimicking testicular cancer in a patient with acute epididymitis.","authors":"Dominik Abt,&nbsp;Mark Meier,&nbsp;Patrick Markart,&nbsp;Hans-Peter Schmid","doi":"10.3109/00365599.2011.562238","DOIUrl":"https://doi.org/10.3109/00365599.2011.562238","url":null,"abstract":"<p><p>Only a few cases of hereditary persistence of α-fetoprotein (HPAFP) have been published. This report presents an association between HPAFP and inflammatory testis disease, to the authors' knowledge, for the first time. HPAFP was diagnosed in a 41-year-old patient with acute epididymitis after exclusion of malignancies and benign diseases.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 5","pages":"354-5"},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.562238","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29777474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.","authors":"Parviz Khajehdehi,&nbsp;Maryam Pakfetrat,&nbsp;Katayoun Javidnia,&nbsp;Fariborz Azad,&nbsp;Leila Malekmakan,&nbsp;Mahshid Hashemi Nasab,&nbsp;Gholamreza Dehghanzadeh","doi":"10.3109/00365599.2011.585622","DOIUrl":"https://doi.org/10.3109/00365599.2011.585622","url":null,"abstract":"<p><strong>Objective: </strong>End-stage renal disease (ESRD) due to type 2 diabetic nephropathy is a very common condition which is increasing in prevalence, and is associated with high global levels of mortality and morbidity. Both proteinuria and transforming growth factor-β (TGF-β) may contribute to the development of ESRD in patients with diabetic nephropathy. Experimental studies indicate that turmeric improves diabetic nephropathy by suppressing TGF-β. Therefore, this study investigated the effects of turmeric on serum and urinary TGF-β, interleukin-8 (IL-8) and tumour necrosis factor-α (TNF-α), as well as proteinuria, in patients with overt type 2 diabetic nephropathy.</p><p><strong>Material and methods: </strong>A randomized, double-blind and placebo-controlled study was carried out in the Diabetes Clinic of the Outpatient Department of Shiraz University of Medical Sciences on 40 patients with overt type 2 diabetic nephropathy, randomized into a trial group (n = 20) and a control group (n = 20). Each patient in the trial group received one capsule with each meal containing 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin (three capsules daily) for 2 months. The control group received three capsules identical in colour and size containing starch for the same 2 months.</p><p><strong>Results: </strong>Serum levels of TGF-β and IL-8 and urinary protein excretion and IL-8 decreased significantly comparing the pre- and post-turmeric supplementation values. No adverse effects related to turmeric supplementation were observed during the trial.</p><p><strong>Conclusion: </strong>Short-term turmeric supplementation can attenuate proteinuria, TGF-β and IL-8 in patients with overt type 2 diabetic nephropathy and can be administered as a safe adjuvant therapy for these patients.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 5","pages":"365-70"},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.585622","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29902577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the outcome of prostate cancer patients with large prostates differ from small prostate size in permanent seed, low dose-rate brachytherapy?","authors":"Sirpa H Aaltomaa,&nbsp;Vesa V Kataja,&nbsp;Atte Räty,&nbsp;Jan-Erik Palmgren,&nbsp;Tapani Lahtinen","doi":"10.3109/00365599.2011.590994","DOIUrl":"https://doi.org/10.3109/00365599.2011.590994","url":null,"abstract":"<p><strong>Objective: </strong>Brachytherapy has good results in the treatment of early prostate cancer (PC). The procedure is challenging in large prostates, and the optimal prostate volume for brachytherapy was previously defined as ≤40 ml. This study analysed the outcome of PC patients with small (group A) and large (group B) prostate volume in prospective data.</p><p><strong>Material and methods: </strong>The material consisted of 535 consecutive patients treated with brachytherapy in Kuopio University Hospital. The mean follow-up time was nearly 6 years. Prostate-specific antigen (PSA) failure was defined as PSA rising ≥2.0 μg/l above nadir. A PSA bounce was defined as a rise in PSA of ≥0.2 μg/l. The causes of death were recorded.</p><p><strong>Results: </strong>A bounce was recorded more frequently in group A (30%) than in group B (18%) (p = 0.006). A bounce correlated with young age predicted a favourable outcome in both groups. PSA failure rate was similar in both groups: 13% and 12% in groups A and B, respectively. Post-treatment PSA ≤0.5 μg/l was the only independent prognostic factor associated with PSA failure in both groups (p < 0.0001, both groups). PC survival was 98.4% in both groups. Overall survival was 91% and 94% in groups A and B, respectively (p = not significant).</p><p><strong>Conclusions: </strong>There were no differences between the PC patients with small and large prostate volumes treated with brachytherapy with respect to PSA failure rate, PC survival or overall survival. All patients, independent of prostate size, are potential candidates for brachytherapy.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 5","pages":"339-45"},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.590994","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29869712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of female stress urinary incontinence: what women find acceptable and the impact of clinical and urodynamic evaluation on their final choice.","authors":"Mostafa Elmissiry,&nbsp;Ayman Mahdy,&nbsp;Gamal Ghoniem","doi":"10.3109/00365599.2011.585620","DOIUrl":"https://doi.org/10.3109/00365599.2011.585620","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was determine what women find acceptable regarding treatment modality for Stress urinary incontinence (SUI) and to assess the impact of clinical and urodynamic evaluation on their final decision.</p><p><strong>Material and methods: </strong>This prospective, institutional review board-approved study included 100 consecutive women with primary SUI. All women were given a questionnaire that included the Urinary Distress Inventory (UDI-6) and the American Urologic Association Quality of Life questionnaire (AUA-QoL6). The patients were also asked to choose one of the four available treatment options, which included major surgeries, minor surgeries, office procedures and medication. Factors affecting the initial choice of treatment were studied. A Q-tip test and multichannel urodynamics were then carried out and the patients were recounseled by the urologist. The patients' final decision was compared with their initial choice and statistical analysis was performed.</p><p><strong>Results: </strong>Initially, 22% patients chose major surgery, 39% minor surgery, 27% an office procedure and 12% medication. This was affected by age, symptom severity and quality of life bother. After clinical and urodynamic evaluation, 34% shifted to a different treatment modality; this correlated significantly with young age, severe symptoms, limited urethral mobility and low Valsalva leak point pressure.</p><p><strong>Conclusions: </strong>Patients' initial choice for treatment of SUI was affected by age, symptom severity and quality of life; however, the final decision was more influenced by the clinical and urodynamic evaluation. It is important to counsel the patients before definitive treatment, to achieve a better outcome.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 5","pages":"326-31"},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.585620","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29902578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary squamous cell prostate cancer after prostate brachytherapy treatment.","authors":"S Aaltomaa,&nbsp;V Kärjä,&nbsp;S Kainulainen","doi":"10.3109/00365599.2011.562237","DOIUrl":"https://doi.org/10.3109/00365599.2011.562237","url":null,"abstract":"<p><p>This report describes the case of a patient with prostate cancerat the age of 59 years, who was treated by interstitial prostate brachytherapy with iodine-125 seeds. Ten years later, he developed a probable secondary squamous cell cancer in his prostate.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 5","pages":"356-8"},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.562237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29761290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.","authors":"Per Olov Hedlund,&nbsp;Robert Johansson,&nbsp;Jan Erik Damber,&nbsp;Inger Hagerman,&nbsp;Peter Henriksson,&nbsp;Peter Iversen,&nbsp;Peter Klarskov,&nbsp;Peter Mogensen,&nbsp;Finn Rasmussen,&nbsp;Eberhard Varenhorst","doi":"10.3109/00365599.2011.585820","DOIUrl":"https://doi.org/10.3109/00365599.2011.585820","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate prognostic risk factors for cardiovascular events during treatment of metastatic prostate cancer patients with high-dose parenteral polyoestradiol phosphate (PEP, Estradurin®) or combined androgen deprivation (CAD) with special emphasis on pretreatment cardiovascular disease.</p><p><strong>Material and methods: </strong>Nine-hundred and fifteen patients with T0-4, Nx, M1, G1-3, hormone- naïve prostate cancer were randomized to treatment with PEP 240 mg i.m. twice a month for 2 months and thereafter monthly, or to flutamide (Eulexin®) 250 mg per os three times daily in combination with either triptorelin (Decapeptyl®) 3.75 mg i.m. per month or on an optional basis with bilateral orchidectomy. Pretreatment cardiovascular morbidity was recorded and cardiovascular events during treatment were assessed by an experienced cardiologist. A multivariate analysis was done using logistic regression.</p><p><strong>Results: </strong>There was a significant increase in cardiovascular events during treatment with PEP in patients with previous ischaemic heart disease (p = 0.008), ischaemic cerebral disease (p = 0.002), intermittent claudication (p = 0.031) and especially when the whole group of patients with pretreatment cardiovascular diseases was analysed together (p < 0.001). In this group 33% of the patients had a cardiovascular event during PEP treatment. In the multivariate analysis PEP stood out as the most important risk factor for cardiac complications (p = 0.029). Even in the CAD group there was a significant increase in cardiovascular events in the group with all previous cardiovascular diseases taken together (p = 0.036).</p><p><strong>Conclusions: </strong>Patients with previous cardiovascular disease are at considerable risk of cardiovascular events during treatment with high-dose PEP and even during CAD therapy. Patients without pretreatment cardiovascular morbidity have a moderate cardiovascular risk during PEP treatment and could be considered for this treatment if the advantages of this therapy, e.g. avoidance of osteopenia and hot flushes and the low price, are given priority.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 5","pages":"346-53"},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.585820","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29902582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of response gene to complement-32 in renal tissue of children with immunoglobulin A nephropathy.","authors":"Xiao-Ling Niu,&nbsp;Xin-Yu Kuang,&nbsp;Zhi-Gang Zhang,&nbsp;Xue-Guang Liu,&nbsp;Zhong-Hua Zhao,&nbsp;Xin Zhang,&nbsp;Hong Xu,&nbsp;Wen-Yan Huang","doi":"10.3109/00365599.2011.585624","DOIUrl":"https://doi.org/10.3109/00365599.2011.585624","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the expression and significance of response gene to complement-32 (RGC-32) in renal tissue of children with immunoglobulin A nephropathy (IgAN).</p><p><strong>Material and methods: </strong>Forty-five patients diagnosed as having IgAN by renal biopsy were enrolled. The expression of RGC-32, α-smooth muscle actin (α-SMA) and transforming growth factor-β(1) (TGF-β(1)) was observed by immunohistostaining. The relationshis between the expression of RGC-32, α-SMA, TGF-β1, degree of renal pathological lesions in IgAN and clinical index were assessed by Spearman correlation.</p><p><strong>Results: </strong>Immunohistostaining analysis showed that RGC-32 protein was present in epithelial cells of renal tubules in normal and IgAN renal tissues. With more severe renal pathological lesions, the expression of RGC-32 in IgAN was increased. The expression of RGC-32 was positively correlated with that of α-SMA, TGF-β(1) and the degree of renal pathological lesions in children with IgAN (p < 0.05), but had no relationship with serum creatinine, urinary N-acetyl-β-d-glucosaminidase/creatinine, urinary microalbuminuria/creatinine, urinary microimmunoglobulin/creatinine or urinary α(1)-microglobulin/creatinine ratio (p > 0.05).</p><p><strong>Conclusion: </strong>Expression of RGC-32 can reflect the degree of renal pathological lesions in IgAN. RGC-32 may participate in the renal tubulointerstitial lesions in children with IgAN, especially in epithelial -mesenchymal transition induced by TGF-β(1).</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 5","pages":"371-6"},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.585624","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30245043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary lithogenesis risk tests: comparison of a commercial kit and a laboratory prototype test.","authors":"Félix Grases,&nbsp;Antonia Costa-Bauzá,&nbsp;Rafel M Prieto,&nbsp;Miguel Arrabal,&nbsp;Tomás De Haro,&nbsp;Juan A Lancina,&nbsp;Carmen Barbuzano,&nbsp;Sergi Colom,&nbsp;Joaquín Riera,&nbsp;Joan Perelló,&nbsp;Bernat Isern,&nbsp;Pilar Sanchis,&nbsp;Antonio Conte,&nbsp;Fernando Barragan,&nbsp;Isabel Gomila","doi":"10.3109/00365599.2011.584551","DOIUrl":"https://doi.org/10.3109/00365599.2011.584551","url":null,"abstract":"<p><strong>Objective: </strong>Renal stone formation is a multifactorial process depending in part on urine composition. Other parameters relate to structural or pathological features of the kidney. To date, routine laboratory estimation of urolithiasis risk has been based on determination of urinary composition. This process requires collection of at least two 24 h urine samples, which is tedious for patients. The most important feature of urinary lithogenic risk is the balance between various urinary parameters, although unknown factors may be involved. The objective of this study was to compare data obtained using a commercial kit with those of a laboratory prototype, using a multicentre approach, to validate the utility of these methods in routine clinical practice.</p><p><strong>Material and methods: </strong>A simple new commercial test (NefroPlus®; Sarstedt AG & Co., Nümbrecht, Germany) evaluating the capacity of urine to crystallize calcium salts, and thus permitting detection of patients at risk for stone development, was compared with a prototype test previously described by this group. Urine of 64 volunteers produced during the night was used in these comparisons. The commercial test was also used to evaluate urine samples of 83 subjects in one of three hospitals.</p><p><strong>Results: </strong>Both methods were essentially in complete agreement (98%) with respect to test results. The multicentre data were: sensitivity 94.7%; specificity 76.9%; positive predictive value (lithogenic urine) 90.0%; negative predictive value (non-lithogenic urine) 87.0%; test efficacy 89.2%.</p><p><strong>Conclusion: </strong>The new commercial NefroPlus test offers fast and cheap evaluation of the overall risk of development of urinary calcium-containing calculi.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 5","pages":"312-8"},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.584551","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29944901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radical cystectomy and urinary diversion in women: impact on sexual function.","authors":"Magdy S El-Bahnasawy,&nbsp;Yasser Osman,&nbsp;Ahmed El-Hefnawy,&nbsp;Afaf Hafez,&nbsp;Mohamed Abdel-Latif,&nbsp;Ahmed Mosbah,&nbsp;Bedir Ali-Eldin,&nbsp;Atallah A Shaaban","doi":"10.3109/00365599.2011.585621","DOIUrl":"https://doi.org/10.3109/00365599.2011.585621","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to assess the impact of radical cystectomy and different forms of urinary diversion on female sexual function.</p><p><strong>Material and methods: </strong>Seventy-three consecutive patients were included in the study. The mean age was 52.3 ± 6.5 years. All of them had undergone non-nerve-sparing radical cystectomy and urinary diversion for invasive bladder cancer. Patients were questioned about their current general relations with their husbands in comparison to the preoperative status. The Female Sexual Function Index (FSFI) was used to assess libido, lubrication, orgasm, satisfaction and painful sexual dysfunction. Patients were asked about any urinary complaints during or after sexual intercourse.</p><p><strong>Results: </strong>Twenty-nine patients (39%) reported worsening relations with their husbands. The mean frequency of sexual relations was 2.3 ± 2.3/month; however, sexual relations had ceased completely in 19 patients (26%). Overall satisfaction among sexually active women worsened in 32 (59.2%) and was completely lost in eight patients (14.8%). Absent libido, difficult intromission, dyspareunia, lack of orgasm and sexually related urinary complaints were reported in 89%, 63%, 48%, 63% and 63% of patients, respectively. The mean FSFI score dropped significantly from 18.3 ± 5.1 to 11.3 ± 7.4 postoperatively (p < 0.001). FSFI scores were significantly higher among patients with orthotopic versus non-orthotopic forms of diversion and also higher among patients with no stoma versus those with stomal forms of diversion.</p><p><strong>Conclusions: </strong>Radical cystectomy and urinary diversion have deleterious impacts on all domains of female sexual function. Female patients with orthotopic and non-stomal diversions had better sexual functions than those with stomal diversions.</p>","PeriodicalId":21543,"journal":{"name":"Scandinavian Journal of Urology and Nephrology","volume":"45 5","pages":"332-8"},"PeriodicalIF":0.0,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/00365599.2011.585621","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29950113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}